Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Genitourinary 3

Conditions

Breast Neoplasms 13144Neoplasms 10492Carcinoma, Non-Small-Cell Lung 6878Prostatic Neoplasms 6276Colorectal Neoplasms 5950Lung Neoplasms 5110Multiple Myeloma 3579Pancreatic Neoplasms 3564Leukemia, Myeloid, Acute 3512Neoplasm Metastasis 3511Carcinoma, Hepatocellular 3277Ovarian Neoplasms 3173Melanoma 3142Stomach Neoplasms 3058Lymphoma 2984Head and Neck Neoplasms 2608Recurrence 2557Precursor Cell Lymphoblastic Leukemia-Lymphoma 2500Leukemia 2362Colonic Neoplasms 2328Brain Neoplasms 2317Lymphoma, Non-Hodgkin 2269Uterine Cervical Neoplasms 2193Rectal Neoplasms 2192Glioblastoma 2018Leukemia, Lymphocytic, Chronic, B-Cell 1992Carcinoma, Renal Cell 1915Squamous Cell Carcinoma of Head and Neck 1880Lymphoma, Follicular 1851Esophageal Neoplasms 1801

Interventions

danusertib 1cabozantinib 1Prednisone 1Nivolumab 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Metastatic Hormone Refractory Prostate Cancer × Clear all
NCT04477512 2025-11-12

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Washington University School of Medicine

Phase 1 Completed
18 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

NCT00766324 2014-05-28

PHA-739358 for Treatment of Hormone Refractory Prostate Cancer

Nerviano Medical Sciences

Phase 2 Completed
118 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

NCT00636090 2013-12-04

Molecular, Genetic, and Genomic Assessments From Patients Treated With RAD001

Duke University

Completed
35 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡